ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Dr.4CENTDAVID

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Oct 03, 2021 5:17pm

139 Views

Post# 33959148

RE:Dr.4CENTDAVID

TopBroker, without all the name calling and cussing can we please have a proper discussion.

Covid is over and I guarantee you we will never see any Revenue or Income from BCNI.

We both know PMN can go up and down on any News, the average movement is 0.04 Cents. For those that Buy at that time will make Money.

TopBroker, I have been successfully running a Government Funded Transit Service for 20+ Years. I highly doubt you have more experience in running a Business and Creating Revenue than I do.

Keep chumming along bud!

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks